Latest Myeloproliferative disease Stories
MOUNTAIN VIEW, Calif., Nov. 3, 2011 /PRNewswire/ -- 23andMe, Inc., an industry leader in personal genetics, announced today that Dr. Ruben Mesa has joined its Myeloproliferative Neoplasms (MPN) research project advisory board. In just over two months since its launch, this first-of-its-kind program has already enrolled over 330 individuals with these rare blood cancers in...
SINGAPORE, Oct. 25, 2011 /PRNewswire/ -- S*BIO Pte Ltd today announced plans to initiate a global Phase 3 clinical program of its novel JAK2 inhibitor pacritinib (SB1518), in the first half of 2012 to further demonstrate its activity and tolerability for the treatment of myelofibrosis (MF). The company is actively exploring partnering opportunities for the advancement of its leading JAK2 program. "Data from Phase 1 and 2 clinical studies have demonstrated that pacritinib is well tolerated...
- CYT387 suppresses multiple signaling pathways, prevents proliferation and induces apoptosis in myeloma cells - - Results published in July online edition of Leukemia - MISSISSAUGA, ON, Aug. 4, 2011 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today reported preclinical results for its JAK1/JAK2 inhibitor CYT387 in multiple myeloma (MM), published in the advance online edition of Leukemia on July 26, 2011. The results demonstrate that CYT387 can inhibit MM...
WHITE PLAINS, N.Y., July 18, 2011 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today announced it has awarded two new Marshall A. Lichtman Specialized Center of Research (SCOR) grants to Frederick W. Alt, Ph.D., Harvard Medical School, and Anthony Green, M.D., Ph.D., University of Cambridge. Each SCOR is valued at $1.25 million a year for five years for a total of $6.25 million. (Logo: http://photos.prnewswire.com/prnh/20110215/NY48642LOGO) The SCOR program is LLS's largest...
VENLO, The Netherlands, June 15, 2011 /PRNewswire/ -- - QIAGEN in exclusive negotiations to purchase 47% initial stake in Ipsogen S.A.and then fully acquire a global leader in hematologic (blood) cancer molecular diagnostics - Ipsogen has a competitive portfolio in blood cancer testing with assays covering 15 biomarkers-including BCR-ABL and JAK2 -for patient profiling and monitoring - Many of Ipsogen's...
- Poster with broader update of trial results to be presented at ASCO - MISSISSAUGA, ON, May 18 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI) (TSX: YM), today reported updated interim results for the first 60 patients with high/intermediate-risk myelofibrosis who have completed a minimum of three cycles of treatment (12 weeks) in its ongoing Phase I/II multi-center study. "In addition to reducing spleen volumes and improving constitutional symptoms, CYT387...
MISSISSAUGA, ON, April 18 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today announced that updated interim anemia response data were reported for the first 60 patients enrolled in the Phase I/II trial of its JAK1/JAK2 inhibitor, CYT387, for the treatment of myelofibrosis. The results were disclosed by Dr. Ayalew Tefferi (Mayo Clinic, Rochester, Minnesota), Chair of the Study, during the First Annual Florence Meeting on Myeloproliferative Neoplasms held in Florence,...
In response to blood cancer re-classifications by the World Health Organization, the MPD Foundation announces it is changing its name to Myeloproliferative Neoplasms (MPN) Research Foundation. Chicago, IL (PRWEB) April 4, 2011 The MPD Foundation, a patient-led foundation dedicated to the discovery of treatments and a cure for three rare blood cancers (myelofibrosis, polycythemia vera, and essential thrombocythemia) announces today a new name for the organization, which will now be known...
Over the past decade, significant advances have been made in the treatment of leukemia through the ongoing development of gene-based targeted therapies. Research that will be presented today at the 52nd Annual Meeting of the American Society of Hematology provides greater understanding of the optimal use of several BCR-ABL inhibitors for the treatment of acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML), and how a new gene target functions for several myeloid...
SINGAPORE, Dec. 6, 2010 /PRNewswire/ -- S*BIO Pte Ltd today announced that data from Phase 1/2 studies for its novel JAK2 inhibitor SB1518 indicates clinical efficacy and good tolerability for the treatment of patients with symptomatic myelofibrosis (MF) and enlarged spleens. SB1518 was also well tolerated in patients with relapsed/refractory lymphoma. Results were presented at the 52nd ASH Annual Meeting and Exposition in Orlando, Fla. "SB1518 showed promising clinical activity with...
